BACKGROUND: The production of therapeutically relevant proteases typically involves activation of a zymogen precursor by external enzymes, which may raise regulatory issues about availability and purity. Recent studies of thrombin precursors have shown how to engineer constructs that spontaneously convert to the mature protease by autoactivation, without the need for external enzymes. OBJECTIVES: Autoactivation is an innovative strategy that promises to simplify the production of proteases of therapeutic relevance, but has not been tested in practical applications. The aim of this study was to provide a direct test of this strategy. METHODS: An autoactivating version of the thrombin mutant W215A/E217A (WE), which is currently in preclinical development as an anticoagulant, was engineered. RESULTS AND CONCLUSIONS: The autoactivating version of WE can be produced in large quantities, like WE made in BHK cells or Escherichia coli, and retains all significant functional properties in vitro and in vivo. The results serve as proof of principle that autoactivation is an innovative and effective strategy for the production of trypsin-like proteases of therapeutic relevance.
BACKGROUND: The production of therapeutically relevant proteases typically involves activation of a zymogen precursor by external enzymes, which may raise regulatory issues about availability and purity. Recent studies of thrombin precursors have shown how to engineer constructs that spontaneously convert to the mature protease by autoactivation, without the need for external enzymes. OBJECTIVES: Autoactivation is an innovative strategy that promises to simplify the production of proteases of therapeutic relevance, but has not been tested in practical applications. The aim of this study was to provide a direct test of this strategy. METHODS: An autoactivating version of the thrombin mutant W215A/E217A (WE), which is currently in preclinical development as an anticoagulant, was engineered. RESULTS AND CONCLUSIONS: The autoactivating version of WE can be produced in large quantities, like WE made in BHK cells or Escherichia coli, and retains all significant functional properties in vitro and in vivo. The results serve as proof of principle that autoactivation is an innovative and effective strategy for the production of trypsin-like proteases of therapeutic relevance.
Authors: Michelle A Berny-Lang; Sawan Hurst; Erik I Tucker; Leslie A Pelc; Ruikang K Wang; Patricia D Hurn; Enrico Di Cera; Owen J T McCarty; András Gruber Journal: Stroke Date: 2011-04-21 Impact factor: 7.914
Authors: Matthew J Flick; Anil K Chauhan; Malinda Frederick; Kathryn E Talmage; Keith W Kombrinck; Whitney Miller; Eric S Mullins; Joseph S Palumbo; Xunzhen Zheng; Naomi L Esmon; Charles T Esmon; Sherry Thornton; Ann Becker; Leslie A Pelc; Enrico Di Cera; Denisa D Wagner; Jay L Degen Journal: Blood Date: 2011-03-24 Impact factor: 22.113
Authors: Laurent O Mosnier; Antonella Zampolli; Edward J Kerschen; Reto A Schuepbach; Yajnavalka Banerjee; José A Fernández; Xia V Yang; Matthias Riewald; Hartmut Weiler; Zaverio M Ruggeri; John H Griffin Journal: Blood Date: 2009-02-24 Impact factor: 22.113
Authors: Madhavi A Jadhav; Whitney N Goldsberry; Sara E Zink; Kelsey N Lamb; Katelyn E Simmons; Carmela M Riposo; Boris A Anokhin; Muriel C Maurer Journal: Biochim Biophys Acta Proteins Proteom Date: 2017-07-04 Impact factor: 3.036
Authors: Erik I Tucker; Norah G Verbout; Brandon D Markway; Michael Wallisch; Christina U Lorentz; Monica T Hinds; Joseph J Shatzel; Leslie A Pelc; David C Wood; Owen J T McCarty; Enrico Di Cera; András Gruber Journal: Blood Date: 2020-02-27 Impact factor: 22.113